



Study of Testosterone and rHGH in Facioscapulohumeral Muscular Dystrophy (FSHD)

Purpose:

Researchers at the University of Rochester (Rochester, New York) are looking for individuals with FSHD who are interested in participating in a research study to learn more about a potential symptomatic therapy for FSHD. This study may help determine if a combination of drugs (recombinant human growth hormone [rHGH] and testosterone) can be safely given to patients with FSHD and possibly improve walking, strength, muscle mass, quality of life, and functional ability.

What's involved?

The study involves five visits (one with an overnight stay) at the University of Rochester. Travel costs may be reimbursed up to \$500 per visit. Study procedures include taking the study drugs (testosterone and rHGH), a physical exam, collection of blood samples, muscle strength and function testing, questionnaires, EKGs, DEXA scans. There is no cost to you to participate, and you will be provided an honorari-

um after completing four of the visits.

You may be eligible to participate if:

- You are a man with FSHD
- You are 18-65 years old
- You are able to walk

For more information, please contact:

Liz Luebbe Study Coordinator University of Rochester Medical Center Phone: 585-275-7867 Email: elizabeth_luebbe@urmc.rochester.edu



Sponsored by the National Institutes of Health (NIH) and Pfizer

Conducted by Dr. Chad Heatwole at the University of Rochester

